How does expert advice impact genotypic resistance testing in clinical practice?

Clinical Infectious Diseases

Volumn 37, Issue 5, 2003, Pages 708-713

  Badri, Sheila M ^a,b,c   Adeyemi, Oluwatoyin M ^a,b,c   Max, Blake E ^c,d   Zagorski, Brandon M ^a   Barker, David E ^a,b,c  

^a Jr Hospital of Cook County   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c Department of Medicine   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL PRACTICE; CONTROLLED STUDY; EVALUATION; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INTERPROFESSIONAL RELATIONS; MALE; MUTATION; PROSPECTIVE STUDIES; RESEARCH DESIGN; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 0041830312     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/377266     Document Type: Article

References (11)

1. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 study team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; I4:F83-93.
2. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 1999; 353:2195-9.
3. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-I genotyping and expert advice: the HAVANA trial. AIDS 2002; 16:209-18.
4. Hirsch MS, Brun-Vézinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-I infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000; 283:2417-26.
5. US Department of Health and Human Services, Henry J Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, February 4, 2002 revision. Available at: http://www.aidsinfo.nih/gov/. Accessed 10 June 2002.
6. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendation of the International AIDS Society-USA Panel. JAMA 2000;283:381-90.
7. Hirsch MS, Richman DD. The role of genotypic resistance testing in selecting therapy for HIV. JAMA 2000; 284:1649-50.
8. Condra JH. Resisting resistance: maximizing the durability of antiretroviral therapy. Ann Intern Med 1998; 128:951-4.
9. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 1999; 13:F17-21.
10. Dionisio D, Vivarelli A, Zazzi M, et al. Extent of human immunodeficiency virus type 1 drug resistance as a predictor of virological failure after genotype-guided treatment switch. Clin Infect Dis 2001; 33:706-9.
11. Deeks S, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-80.